Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease

Thorax

Volumn 53, Issue 9, 1998, Pages 803-808

  Fabbri, Leonardo ^a,b   Beghé, Bianca ^a,b   Caramori, Gaetano ^a,b   Papi, Alberto ^a,b   Saetta, Marina ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE PROPIONATE; FORMOTEROL; MUCOLYTIC AGENT; SALMETEROL; STEROID;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; HUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOM;

EID: 0031688558     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.9.803     Document Type: Review

References (96)

1. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. National Institutes of Health, National Heart, Lung and Blood Institute, Publication No. 97-4051A, May 1997.
2. Sheffer AL, ed. Global initiative for asthma. NHLBI/WHO Workshop report. National Institutes of Health, National Heart, Lung and Blood Institute, Publication No. 95 3659, January 1995.
3. Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(Suppl): S77-120.
4. Siafakas NM, Vermeire P, Pride NB, et al on behalf of the Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Resp J 1995;8:1398-420.
5. Calverley P, Pride N. Chronic obstructive pulmonary disease. London: Chapman and Hall Medical, 1995.
6. Ernst P, Fitzgerald JM, Spier S. Canadian asthma consensus conference summary of recommendations. Can Respir J 1996;3:89-100.
7. Fabbri L, Burge PS, Croonenborgh L, et al on behalf of an International Study Group. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48:817-23.
8. Greening AP, Ind PW, Northfield M, on behalf of Allen and Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-24.
9. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
10. Pearlman DS, Chervinsky P, La Force C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
11. Thompson AB, Daughton D, Rohhins RA, et al. Intraluminal airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-37.
12. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
13. Woolcock A, Lundback B, Ringdal OLN, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
14. Pauwels R, Lofdahl CG, Postma DS, et al for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effects of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
15. The British Thoracic Society, the National Asthma Campaign, the Royal College of Physicians of London in association with the General Practitioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society and the Royal College of Paediatrics and Child Health. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52(Suppl 1):S1-21.
16. LeSon S, Gershwin ME. Risk factors for intubation of adult asthmatic patients. J Asthma 1995;32:97-104.
17. LeSon S, Gershwin ME. Risk factors for asthmatic patients requiring intubation. II. Observations in teenagers. J Asthma 1995;32:379-89.
18. LeSon S, Gershwin ME. Risk factors for asthmatic patients requiring intubation. III. Observations in young adults. J Asthma 1996;33:27-35.
19. Pacht ER, Lingo S, St John RC. Clinical feature, management, and outcome of patients with severe asthma admitted to the intensive care unit. J Asthma 1995;32: 373-7
20. Connors AF, Dawson NV, Thomas C, et al for the SUPPORT Investigators. Outcomes following acute exacerbations of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996;154:959-67.
21. Lung and Asthma Information Agency. Trends in hospital admissions for asthma. Factsheet 96/2.
22. Lung and Asthma Information Agency. Respiratory morbidity in general practice, 1971-1991. Factsheet 96/3.
23. Chan-Yeung M, Chang JH, Manfreda J, et al. Changes in peak flow, symptom score, and the use of medications during acute exacerbations of asthma. Am J Respir Crit Care Med 1996;154:889-93.
24. Rodriguez-Roisin R. Pathophysiology. In: Brewis RAL, Corrin B, Geddes DM, Gibson GJ, eds. Respiratory medicine. 2nd ed. London: WB Saunders, 1995: 1161-77
25. Rodriguez-Roisin R. Acute severe asthma: pathophysiology and pathohiology of gas exchange abnormalities. Eur Respir J 1997;10:1380-91.
26. Adelroth E, Rosenhall L, Glennow C. High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics: a two year study. Allergy 1985;40:58-64.
27. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887-91.
28. Picado C. Classification of severe asthma exacerbations: a proposal. Eur Respir J 1996;9:1775-8.
29. Collet JP, Shapiro S, Ernest P, et al. Effect of an immuno-stimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:1719-24.
30. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
31. Miravitlles M, Mayordomo C, Sànchez-Agudo L, et al and EOLO group. Drug usage in acute exacerbations of COPD in general practice. Am J Respir Crit Care Med 1996; 153(Suppl):A825.
32. Fuso L, Incalzi RA, Pistilli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995;98:272-7.
33. Seneff MG, Douglas P, Wagner P, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-7.
34. Vestbo J, Prescott E, Lange P and The Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530-5.
35. Fletcher CM, Peto R, Tinker C, et al. The natural history of chronic bronchitis and emphysema: an eigth-year study of early chronic obstructive lung disease in working men in London. New York: Oxford University Press, 1976: 272.
36. Seemungal T, Paul EA, Donaldson GC, et al for the East London COPD Collaborative Group. Factors predisposing to exacerbations in patients with COPD. Thorax 1996; 51(Suppl 3):A19, S74.
37. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Resp Crit Care Med 1994;150:1646-52.
38. Fletcher C, Peto R. The natural history of chronic airflow obstrution. BMJ 1977;1:1645-8.
39. Arrighi HM. US asthma mortality: 1941 to 1989. Ann Allergy Asthma Immunol 1995;74:321-6.
40. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-8.
41. Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admission for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996;154:654-60.
42. Corne JM, Smith S, Schreiber J, et al. The role of rhinovirus in exacerbations of asthma in adults. Am J Respir Crit Care Med 1997;155(Suppl):A63
43. Sokhandan M, McFadden ER, Huang YT, et al. The contribution of respiratory viruses to severe exacerbations of asthma in adults. Chest 1995;107:1570-5.
44. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993;307:982-6.
45. Corne JM, Holgate ST. Mechanisms of virus induced exacerbations of asthma. Thorax 1997;52:380-9.
46. Fraenkel DJ, Bardin PG, Sanderson G, et al. Lower airways inflammation during rhinovirus colds in normal and in asthmatics subjects. Am J Respir Crit Care Med 1995;151: 879-86.
47. Calhoun WJ, Dick EC, Schwartz LB, et al. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994;94:2200-8.
48. Bloemen PGM, Henricks PAJ, Nijkamp FP. Cell adhesion molecules and asthma. Clin Exp Allergy 1997;27:128-41.
49. Staunton DE, Merluzzi VJ, Rothlein R, et al. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989;56:849-53.
50. Perrin B, Cartier A, Ghezzo H. Reassesment of the temporal patterns of bronchial obstruction after exposure to occupational sensitizing agents. J Allergy Clin Immunol 1991;87:630-9.
51. Sterk PJ, Fabbri LM, Quanjer PhH, et al. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report of Working Party, Standardization of Lung Function Tests, European Community for Steel and Coal, Official Statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl 16):53-83.
52. Fagon JY, Chastre J. Severe exacerbations of COPD patients: the role of pulmonary infections. Semin Respir Infect 1996;11:109-18.
53. Hogg JC, Hegele RG. Viral infection as a precipitating factor. In: Derenne J-P, Whitelaw WA, Similowski T, eds. Acute respiratory failure in chronic obstructive pulmonary disease. Lung Biology in Health and Disease, Vol 92. New York: Marcel Dekker, 1996: 319-35.
54. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in six European cities: results from the APHEA project. Eur Respir J 1997;10:1064-71.
55. Dinh-Xuan AT, Higenbottam TW. Pulmonary vascular reactivity in acute respiratory failure of chronic obstructive pulmonary disease. In: Derenne J-P, Whitelaw WA, Similowski T, eds. Acute respiratory failure in chronic obstructive pulmonary disease. Lung Biology in Health and Disease, Vol 92. New York: Marcel Dekker, 1996: 303-17.
56. King M, Rubin BK. Mucus physiology and pathophysiology: therapeutic aspects. In: Derenne J-P, Whitelaw WA, Similowski T, eds. Acute respiratory failure in chronic obstructive pulmonary disease. Lung Biology in Health and Disease, Vol 92. New York: Marcel Dekker, 1996: 391-411.
57. Grassino AE, Begin P. Role of respiratory muscle dysfunction in ventilatory failure. In: Derenne J-P, Whitelaw WA, Similowski T, eds. Acute respiratory failure in chronic obstructive pulmonary disease. Lung Biology in Health and Disease, Vol 92. New York: Marcel Dekker, 1996: 65-78.
58. Barbera JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997;10:1285-91.
59. Pariente R, Whitelaw WA. Thromboembolic disease as a precipitating factor. In: Derenne J-P, Whitelaw WA, Similowski T, eds. Acute respiratory failure in chronic obstructive pulmonary disease. Lung Biology in Health and Disease, Vol 92. New York: Marcel Dekker, 1996: 413-27.
60. Worley BD, Peacock M, Burke B, et al. The incidence of deep venous thrombosis in patients with chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 1997;155(Suppl):A594.
61. Gibson PG, Wong JO, Hepperle MJE, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992;22:525-32.
62. Turner MO, Hussack P, Sears MR, et al. Exacerbations of asthma without sputum eosinophilia. Thorax 1995;50: 1057-61.
63. Fahy JV, Kim KW, Liu J, et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;4:843-52.
64. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies and bronchoalveolar lavage. Am J Respir Crit Care 1995;152: 1926-31.
65. Piattella M, Maestrelli P, Saetta M, et al. Sputum eosinophilia during mild exacerbations and sputum neutrophilia during severe exacerbations of COPD. Am J Respir Crit Care Med 1996;153(Suppl):A822.
66. Synek M, Beasley R, Frew AJ, et al. Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med 1996;154:224-30.
67. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147:405-10.
68. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997;10:292-300.
69. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma: a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993;148:713-9.
70. Reid LM. The presence or absence of bronchial mucus in fatal asthma. J Allergy Clin Immunol 1987;80:415-6.
71. Nagai A, West WW, Paul JL, et al. The National Institute of Health Intermittent Positive-Pressure Breathing Trial. Pathology studies. Am Rev Respir Dis 1985;132:937-45.
72. Nagai A, West WW, Thurlbeck WM. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Pathology studies, II: Correlation between morphologic findings, clinical findings and evidence of expiratory air-flow obstruction. Am Rev Respir Dis 1985;132:946-53.
73. Snider GL. Chronic obstructive pulmonary disease: a continuing challenge. Am Rev Respir Dis 1986;133:942-4.
74. Beveridge RC, Grunfeld AF, Hodder RV, et al for the CAEP/CTS Asthma Advisory Committee. Guidelines for the emergency management of asthma in adults. Can Med Assoc J 1996;155:25-37.
75. Cochrane GM. Acute severe asthma: oxygen and high dose β agonist during transfer for all. Thorax 1995;50:1-2.
76. Fitzgerald JM, Grunfeld A, Pare PD, et al and the Canadian Combivent Study Group. The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Chest 1997;111:311-5.
77. McFadden ER Jr, El Sanadi N, Strauss L, et al. The influence of parasympatholytics on the resolution of acute attacks of asthma. Am J Med 1997;102:7-13.
78. Garrett JE, Town GI, Rodwell P, et al. Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. J Allergy Clin Immunol 1997;100:165-70.
79. Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50:834-7.
80. Murphy DG, McDermott MF, Rydman RJ, et al. Aminophylline in the treatment of acute asthma when β-adrenergic agents and steroids are provided. Arch Intern Med 1993;153:1784-8.
81. Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;107:305-9.
82. McFadden ER Jr. Role of glucocorticoids in the therapy of acute asthma. In: Schleimer RP, Busse WW, O'Byrne PM, eds. Inhaled glucocorticoids in asthma: mechanisms and clinical actions. Lung Biology in Health and Disease, Vol 97. New York: Marcel Dekker, 1997: 507-19.
83. Niewoehner DE, Erbland ML. Systemic corticosteroids in COPD: an unresolved clinical dilemma. Chest 1996;110: 867-9.
84. Paggiaro PL, Dahle R, Bakran I, et al. Multicenter randomized placebo controlled trial of inhaled fluticasone propionate in patients with COPD. Lancet 1998;351:773-80.
85. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
86. Sachs AP, Koeter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995;50:758-63.
87. Xinogalos S, Duratsoa D, Varonos D. Clinical effectiveness of Broncho-Vaxon in patients with chronic bronchitis. Int J Immunother 1993;9:135-42.
88. Maestroni GJM, Lose GA. Clinical and immunibiological effects of an orally administered bacterial extract. Int J Immunopharmacol 1984;6:111-7.
89. Keller R. Multicentre double blind study of the Broncho-Vaxom in chronic bronchitis. Prax Klin Pneumol 1984;38: 225-8.
90. Mauel J, Van Pharm T, Kreis B, et al. Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. Int J Immunopharmacol 1989;11:636-45.
91. The AMETHIST Italian Study Group. Efficacy of 12 month therapy with oral ambroxol in preventing exacerbations in patients with chronic bronchitis. Double-blind randomized, multicenter placebo controlled study. Chest 1997; 112(Suppl 3):22S.
92. Martinez FD, Wright AL, Taussig LM, et al and the Group Health Medical Associates. Asthma and wheezing in the first six years of life. N Engl J Med 1995;332:133-8.
93. 1: the Lung Health Study. JAMA 1994;272:1497-505.
94. Pauwels RA, Lofdahl CG, Pride NB, et al. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992;5:1254-61.
95. Sherwood Burge P, Calverley P, for the Isolde Study Group. Inhaled steroids in obstructive lung disease in Europe, the Isolde trial; protocol and progress. Am J Respir Crit Care Med 1994;149(Suppl):A312.
96. Brondum E, Vestbo J, Lange P, et al. The Copenhagen City Lung Study. A clinical trial of inhaled corticosteroids in COPD: design and progress. Am J Respir Crit Care Med 1997;155(Suppl):A590.